



Living Cell Technologies Limited

ACN: 104 028 042
ASX: LCT
OTCQB: LVCLY

ASX ANNOUNCEMENT

NTCELL to be Produced in Australia for 1st Time Under UTS Research Agreement

Highlights

- **LCT signs Research Agreement with University of Technology Sydney to utilise university facilities in Sydney**
- **NTCELL to be produced in Australia for 1st time, advancing third clinical trial of NTCELL in Parkinson's disease**

Sydney, Australia & Auckland, New Zealand - 30 March 2022 – Living Cell Technologies (ASX: LCT) has advanced plans for a third clinical trial of NTCELL in Parkinson's disease, following the signing of a Research Agreement with the University of Technology Sydney (UTS) and the Australian Foundation for Diabetes Research (AFDR).

The UTS agreement will allow university facilities to be used to optimise the production of NTCELL in Australia for the first time, prior to the third clinical trial. Once approved by import authorities, porcine brain tissue (choroid plexus) will be shipped to Sydney from research partner NZeno's pig facility in Invercargill, New Zealand.

Once the Australian production of NTCELL has been optimised at UTS, the tissue will be sent to a Good Manufacturing Practice (GMP) facility, where it will be manufactured under conditions suitable for it to be used clinically.

Approval for the use of the encapsulated pig tissue will need to be obtained from a Human Research Ethics Advisory Committee and the Therapeutic Goods Administration.

The NTCELL clinical trial for people with early to mid-stage Parkinson's disease is likely to be the first xenotransplantation trial carried out in Australia after earlier trials in New Zealand.

LCT Executive Chairman, Professor Bernie Tuch, said: "This is another key step as we advance this potentially groundbreaking research in Australia, following in the footsteps of New Zealand researchers.

"Optimising the production of encapsulation pig choroid plexus in Australia is a necessary measure before it is manufactured under GMP conditions for the clinical trial.

"We look forward to getting this work underway as soon as possible, given the pressing need for new treatments for Parkinson's disease and its impact on the community."

The first trial participants are expected to receive treatment in 2024.

More than 10 million people worldwide are living with Parkinson's disease, including 100,000 Australians, with the disease estimated to cost the Australian community an estimated \$10 billion per year.

The research agreement follows LCT's announcement on 24 January of the signing of a Services Agreement with NZeno, with the New Zealand biotech breeding and maintaining pigs to provide tissue for the clinical trial.

Authorised for release by the Board of Living Cell Technologies Limited.

– Ends –

For further information: www.lctglobal.com

At the Company: Bernie Tuch Chief Executive Mobile: +61 411 461 604 bernietuch@lctglobal.com	For media queries: Anthony Fensom Republic PR Mobile: +61 407 112 623 anthony@republicpr.com.au
---	---

About NTCELL

NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells that are sourced from a unique herd of designated pathogen-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands. Choroid plexus cells are naturally occurring 'support' cells for the brain and secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with alginate to protect them from attack by the immune system. Therefore, no immunosuppressive regimen needs to be administered to recipients.

About Living Cell Technologies

Living Cell Technologies Limited (ASX:LCT) is an Australasian biotechnology company that is focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease.

LCT is listed on the Australian (ASX:LCT) and US (OTCQB:LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in Australia and New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter, Facebook or LinkedIn.

Forward-looking statements

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.